Zydus hits 52-week high, can the optimism continue?
A quarterly results development with market-wide reach.
· LiveMint Markets
Zydus Lifesciences has gained 32% in 2026, helped by favourable US FDA inspections, resilient India growth and a strong pipeline, but US weakness and margin pressure remain key risks.
The analysis
This is an USFDA action event. US regulatory status gates the export revenue that drives most Indian pharma earnings. A clearance reopens filings from that site; an alert freezes them, and the impact lands over quarters rather than days.
Related coverage
TCS dividend 2026 record date, Q2 FY 2027 results announcement date and time, schedule, dividend history - Details
Q2 results today: TCS, Indian Bank, 4 others set to announce earnings
TCS shares rise ahead of Q2 results; Mphasis, Coforge, Infosys also gain; here's why
Fino Payments Bank share price rallies 17% after Q2 business update
ICICI Prudential Life Insurance to focus on growing absolute VNB amid slump in FY24